Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1775 and Carboplatin in p53 Mutated Ovarian Cancer
NCT01164995Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2010
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of adavosertib in epithelial ovarian cancer (EOC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), Cervical Cancer (CC), endometrial cancer (EC), sponsored by Netherlands Cancer Institute. Started Jul 2010; status: completed.
02
Drugs
adavosertib
03
Conditions
epithelial ovarian cancer (EOC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01164995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01164995.